Structure Therapeutics (GPCR) to Release Earnings on Thursday

Structure Therapeutics (NASDAQ:GPCR) is expected to announce its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $68.36 on Thursday. The stock has a market capitalization of $4.15 billion, a P/E ratio of -56.03 and a beta of -2.06. The business has a 50 day simple moving average of $75.09 and a two-hundred day simple moving average of $44.32. Structure Therapeutics has a 12 month low of $13.22 and a 12 month high of $94.90.

Wall Street Analyst Weigh In

Several research firms recently commented on GPCR. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Thursday, January 22nd. The Goldman Sachs Group upgraded shares of Structure Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 20th. Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, January 31st. BMO Capital Markets reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, January 6th. Finally, Morgan Stanley raised their target price on shares of Structure Therapeutics from $120.00 to $125.00 and gave the stock an “overweight” rating in a research note on Friday, December 12th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $106.20.

Institutional Trading of Structure Therapeutics

Several hedge funds have recently made changes to their positions in GPCR. Geode Capital Management LLC raised its position in shares of Structure Therapeutics by 18.5% during the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after buying an additional 8,444 shares during the period. Invesco Ltd. increased its stake in Structure Therapeutics by 7.6% during the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after acquiring an additional 30,162 shares during the last quarter. Marshall Wace LLP raised its position in Structure Therapeutics by 474.9% in the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after purchasing an additional 145,434 shares during the period. Jump Financial LLC lifted its stake in shares of Structure Therapeutics by 105.9% in the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after purchasing an additional 32,524 shares during the last quarter. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Structure Therapeutics during the 2nd quarter worth $3,480,000. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.